Rheumatology:抗MDA5+皮肌炎患者RPILD和死亡率风险的时间依赖性变化,中国272例队列研究

2022-08-20 紫菀款冬 MedSci原创

调查抗MDA5+皮肌炎(DM)患者发生快速进展性间质性肺病(RPILD)和死亡的风险是否具有时间依赖性。

目的:抗黑色素瘤分化相关基因5阳性(抗MDA5+皮肌炎(DM)快速进展性间质性肺病(RPILD)密切相关,并与高死亡率相关。然而,关于RPILD的时间依赖性风险和疾病进展期间死亡的数据有限。该研究旨在调查抗MDA5+DM患者发生RPILD和死亡的风险是否具有时间依赖性

方法:评估了272例抗MDA5+DM患者队列。收集抗MDA5+患者的临床特征,并使用cox回归分析RPILD和死亡的独立危险因素。并描述了RPILD和死亡风险随时间的变化及其潜在的临床意义。

结果:共有272名抗MDA5+DM患者参与该研究。

根据多变量cox回归分析,病程短、CRP水平高、抗Ro52阳性、抗MDA5滴度高( ++~+++)是RPILD的独立危险因素高CK水平、高CRP水平和RPILD是死亡的独立危险因素

>90%的RPILD和84%的死亡率发生在发病后的前6个月 。值得注意的是,前3个月是一个特别高风险的时期,发生了50%的RPILD和46%的死亡。在中位随访12年期间,与RPILD和死亡率相关的危险随着时间的推移而减少

结论:这些结果表明抗MDA5+DM患者的RPILD和死亡率风险存在显著的时间依赖性变化,为估计疾病进展和不良预后提供了一个截止时间窗

 

文献来源:

ou H, Wang L, Wang J, et al. Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China [published online ahead of print, 2022 Aug 12]. Rheumatology (Oxford). 2022;keac450. doi:10.1093/rheumatology/keac450

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1662035, encodeId=6cbc166203583, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79025361884, createdName=ms3994565386320060, createdTime=Tue Mar 21 04:22:21 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943457, encodeId=2109194345e54, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Aug 25 01:22:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062607, encodeId=6c0d206260e14, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 10 00:22:21 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943565, encodeId=7b6b194356573, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Oct 04 15:22:21 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309293, encodeId=eb9c1309293c6, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 18 12:22:21 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1662035, encodeId=6cbc166203583, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79025361884, createdName=ms3994565386320060, createdTime=Tue Mar 21 04:22:21 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943457, encodeId=2109194345e54, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Aug 25 01:22:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062607, encodeId=6c0d206260e14, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 10 00:22:21 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943565, encodeId=7b6b194356573, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Oct 04 15:22:21 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309293, encodeId=eb9c1309293c6, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 18 12:22:21 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
    2022-08-25 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1662035, encodeId=6cbc166203583, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79025361884, createdName=ms3994565386320060, createdTime=Tue Mar 21 04:22:21 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943457, encodeId=2109194345e54, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Aug 25 01:22:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062607, encodeId=6c0d206260e14, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 10 00:22:21 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943565, encodeId=7b6b194356573, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Oct 04 15:22:21 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309293, encodeId=eb9c1309293c6, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 18 12:22:21 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1662035, encodeId=6cbc166203583, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79025361884, createdName=ms3994565386320060, createdTime=Tue Mar 21 04:22:21 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943457, encodeId=2109194345e54, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Aug 25 01:22:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062607, encodeId=6c0d206260e14, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 10 00:22:21 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943565, encodeId=7b6b194356573, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Oct 04 15:22:21 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309293, encodeId=eb9c1309293c6, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 18 12:22:21 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
    2022-10-04 wetgdt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1662035, encodeId=6cbc166203583, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79025361884, createdName=ms3994565386320060, createdTime=Tue Mar 21 04:22:21 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943457, encodeId=2109194345e54, content=<a href='/topic/show?id=2e09156e0c2' target=_blank style='color:#2F92EE;'>#RPI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15670, encryptionId=2e09156e0c2, topicName=RPI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Aug 25 01:22:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062607, encodeId=6c0d206260e14, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 10 00:22:21 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943565, encodeId=7b6b194356573, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Oct 04 15:22:21 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309293, encodeId=eb9c1309293c6, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 18 12:22:21 CST 2022, time=2022-08-18, status=1, ipAttribution=)]

相关威廉亚洲官网

European Radiology:从影像学角度,明确特发性炎症性肌病与特异性自身抗体之间的关系

特发性炎症性肌病(IIMs)是一组罕见的、异质性的多系统自身免疫性疾病,以骨骼肌、皮肤和其他器官受累为主要特征。间质性肺病(ILD)是最常见的肌肉外IIM受累表现之一。

Rheumatology:超氧化物歧化酶在与间质性肺病相关的抗MDA5阳性皮肌炎中的价值评估

探讨抗黑色素瘤分化相关基因5抗体阳性皮肌炎(抗MDA5阳性DM)患者血清超氧化物歧化酶(SOD)与间质性肺病(ILD)的关系。

ARD:肺分子特征的综合分析揭示了系统性硬化症相关间质性肺病的关键驱动因素

肺组织的综合转录组分析揭示了 SSc-ILD 中纤维化的关键特征。基于网络的贝叶斯方法提供了对适用于治疗 SSc-ILD 的关键调控基因和分子靶点的深入见解。

第二届长三角间质性肺病论坛暨第四届呼吸疾病诊治论坛

第二届长三角间质性肺病论坛暨第四届呼吸疾病诊治论坛

间质性肺病的肺动脉高压研究进展

肺循环领域的疾病治疗方法已经取得了一些进展,但 PH-ILD 治疗的持续创新直到最近才出现,主要集中在 IIP,主要集中在 IPF。

European Radiology:对于偶然发现的肺部间质性改变,究竟有何临床意义?

现阶段,人们已经认识到肺间质异常(ILAs)与不良的临床预后和死亡率的增加有关,影像学进展率从2年的20%到5年的63%不等。